共查询到20条相似文献,搜索用时 19 毫秒
1.
Ward SE Johnson CN Lovell PJ Scott CM Smith PW Stemp G Thewlis KM Vong AK Watson JM 《Bioorganic & medicinal chemistry letters》2007,17(18):5214-5217
A series of 5-(piperidinylethyloxy)quinoline 5-HT(1) receptor ligands have been studied by elaboration of the series of dual 5-HT(1)-SSRIs reported previously. These new compounds display a different pharmacological profile with potent affinity across the 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles and CNS penetration. 相似文献
2.
Simon E. Ward Peter Eddershaw Sean T. Flynn Laurie Gordon Peter J. Lovell Susan H. Moore Claire M. Scott Paul W. Smith Kevin M. Thewlis Paul A. Wyman 《Bioorganic & medicinal chemistry letters》2009,19(2):428-432
A series of 5-(piperidinylethyloxy)quinoline 5-HT1 receptor ligands have been studied by elaboration of the series of dual 5-HT1-SSRIs reported previously. These new compounds display a different in vitro pharmacological profile with potent affinity across the 5-HT1A, 5-HT1B and 5-HT1D receptors and selectivity against the serotonin transporter. Furthermore, they have improved pharmacokinetic profiles and CNS penetration. 相似文献
3.
A series of serotonin 5-HT1B ligands were synthesized and evaluated for their potency and selectivity against other 5-HT receptor subtypes. Many of these new compounds displayed high affinity and selectivity for the 5-HT1B receptor and compound 6c was found to have the in vitro binding profile necessary for development as a PET radioligand. 相似文献
4.
Discovery of potent,selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors
Meizhong Jin Jing Wang Andrew Kleinberg Mridula Kadalbajoo Kam W. Siu Andrew Cooke Mark A. Bittner Yan Yao April Thelemann Qunsheng Ji Shripad Bhagwat Kristen M. Mulvihill Josef A. Rechka Jonathan A. Pachter Andrew P. Crew David Epstein Mark J. Mulvihill 《Bioorganic & medicinal chemistry letters》2013,23(4):979-984
This Letter describes the medicinal chemistry effort towards a series of novel imidazo[1,5-a]pyrazine derived inhibitors of ACK1. Virtual screening led to the discovery of the initial hit, and subsequent exploration of structure–activity relationships and optimization of drug metabolism and pharmacokinetic properties led to the identification of potent, selective and orally bioavailable ACK1 inhibitors. 相似文献
5.
《Bioorganic & medicinal chemistry》2020,28(11):115524
Structural modification of a 1,4-benzodiazepin-2-one-based PTHR1 antagonist 5, a novel type of PTHR1 antagonist previously synthesized in our laboratories, yielded compound 10, which had better chemical stability than compound 5. Successive optimization of the lead 10 improved aqueous solubility, metabolic stability, and animal pharmacokinetics, culminating in the identification of DS37571084 (12). Our study paves the way for the discovery of novel and orally bioavailable PTHR1 antagonists. 相似文献
6.
Kevin G. Liu Jennifer R. Lo Thomas A. Comery Guo Ming Zhang Jean Y. Zhang Dianne M. Kowal Deborah L. Smith Li Di Edward H. Kerns Lee E. Schechter Albert J. Robichaud 《Bioorganic & medicinal chemistry letters》2009,19(9):2413-2415
As part of our continuing efforts to identify therapeutics for CNS diseases, such as schizophrenia and Alzheimer’s disease (AD), we have been focused on the 5-HT6 receptor in an attempt to identify ligands as a potential treatment for cognitive dysfunction. Herein we report the identification of a novel series of 1-sulfonylindazole derivatives as potent and selective 5-HT6 antagonists. The synthesis and SAR of this class of compounds are reported. Several potent compounds in both binding and cyclase functional assays also display good selectivity, microsomal stability, solubility, and brain penetration as well as low cytochrome P450 inhibition. One compound exemplified in this series showed 24% oral bioavailability and in vivo efficacy in a NOR cognition model at 10 mg/kg following an oral administration in rats. 相似文献
7.
Hanbiao Yang Xiao-Fa Lin Fernando Padilla Stephen D. Gabriel Gabrielle Heilek Changhua Ji Surya Sankuratri André deRosier Pamela Berry David M. Rotstein 《Bioorganic & medicinal chemistry letters》2009,19(1):209-213
Replacement of the cyclic carbamate in our previously disclosed 1-oxa-3,9-diazaspiro[5.5]undecan-2-one template led to the discovery of two novel series of 3,9-diazaspiro[5.5]undecane and undeca-2-one CCR5 antagonists. The synthesis, SAR, and antiviral activities of these two series are described. One compound (32) was found to have attractive combination of antiviral potency, selectivity, and pharmacokinetic profile. The asymmetric synthesis of 32 was also accomplished and both enantiomers were equally potent. 相似文献
8.
Modica M Santagati M Santagati A Russo F Cagnotto A Goegan M Mennini T 《Bioorganic & medicinal chemistry letters》2000,10(10):1089-1092
This paper reports the synthesis and affinities on the 5-HT1A versus the alpha1A receptors of new arylpiperazinylalkylthiothienopyrimidine and thiadiazole derivatives 16-24. Arylpiperazines 16-23 show affinities values in the nanomolar range for the 5-HT1A receptor. The compound 16 is highly potent (Ki 0.26 nM, selectivity 28), the derivatives 20 and 21 are less potent, but highly selective (Ki 9.40 and 5.06 nM, selectivity 207 and 73, respectively). 相似文献
9.
Ji Q Gao J Wang J Yang C Hui X Yan X Wu X Xie Y Wang MW 《Bioorganic & medicinal chemistry letters》2005,15(11):2891-2893
A series of estrogen receptor ligands based on benzothieno[3,2-b]indole were synthesized and their binding affinity for estrogen receptor subtypes (ERalpha and ERbeta) and effects on mouse uterus and bone were evaluated. Some of these compounds showed strong binding affinity to ER and significantly increased the bone mineral density of ovariectomized mice. 相似文献
10.
Patel D Jain M Shah SR Bahekar R Jadav P Joharapurkar A Dhanesha N Shaikh M Sairam KV Kapadnis P 《Bioorganic & medicinal chemistry letters》2012,22(2):1111-1117
A novel series of pTyr mimetics containing triaryl-sulfonamide derivatives (5a-r) are reported as potent and selective PTP1B inhibitors. Some of the test compounds (5o and 5p) showed excellent selectivity towards PTP1B over various PTPs, including TCPTP (in vitro). The lead compound 5o showed potent antidiabetic activity (in vivo), along with improved pharmacokinetic profile. These preliminary results confirm discovery of highly potent and selective PTP1B inhibitors for the treatment of T2DM. 相似文献
11.
Xiao Ding Xuedong Dai Kai Long Cheng Peng Daniele Andreotti Paul Bamborough Andrew J. Eatherton Colin Edge Karamjit S. Jandu Paula L. Nichols Oliver J. Philps Luigi Piero Stasi Zehong Wan Jia-Ning Xiang Kelly Dong Pamela Dossang Ming-Hsun Ho Yi Li Feng Ren 《Bioorganic & medicinal chemistry letters》2017,27(17):4034-4038
Leucine-rich repeat kinase 2 (LRRK2) has been suggested as a potential therapeutic target for Parkinson’s disease. Herein we report the discovery of 5-substituent-N-arylbenzamide derivatives as novel LRRK2 inhibitors. Extensive SAR study led to the discovery of compounds 8e, which demonstrated potent LRRK2 inhibition activity, high selectivity across the kinome, good brain exposure, and high oral bioavailability. 相似文献
12.
Joanne L. Thomson Wesley P. Blackaby Andrew S.R. Jennings Simon C. Goodacre Andrew Pike Steve Thomas Terry A. Brown Alison Smith Gopalan Pillai Leslie J. Street Richard T. Lewis 《Bioorganic & medicinal chemistry letters》2009,19(8):2235-2239
A series of heterocyclic sulfonamides have been developed which are potent and selective inhibitors of hGlyT1. SAR studies to optimise the in vitro and in vivo properties are described. Optimisation of the central scaffold resulted in cyclohexane sulfones 28 and 29, which have good PK properties and show promise for further development. 相似文献
13.
Jun Liang Sharada Labadie Birong Zhang Daniel F. Ortwine Snahel Patel Maia Vinogradova James R. Kiefer Till Mauer Victor S. Gehling Jean-Christophe Harmange Richard Cummings Tommy Lai Jiangpeng Liao Xiaoping Zheng Yichin Liu Amy Gustafson Erica Van der Porten Weifeng Mao Lesley Murray 《Bioorganic & medicinal chemistry letters》2017,27(13):2974-2981
A high-throughput screening (HTS) of the Genentech/Roche library identified a novel, uncharged scaffold as a KDM5A inhibitor. Lacking insight into the binding mode, initial attempts to improve inhibitor potency failed to improve potency, and synthesis of analogs was further hampered by the presence of a C–C bond between the pyrrolidine and pyridine. Replacing this with a C–N bond significantly simplified synthesis, yielding pyrazole analog 35, of which we obtained a co-crystal structure with KDM5A. Using structure-based design approach, we identified 50 with improved biochemical, cell potency and reduced MW and lower lipophilicity (Log D) compared with the original hit. Furthermore, 50 showed lower clearance than 9 in mice. In combination with its remarkably low plasma protein binding (PPB) in mice (40%), oral dosing of 50 at 5 mg/kg resulted in unbound Cmax ~2-fold of its cell potency (PC9 H3K4Me3 0.96 μM), meeting our criteria for an in vivo tool compound from a new scaffold. 相似文献
14.
Mathes BM Hudziak KJ Schaus JM Xu YC Nelson DL Wainscott DB Nutter SE Gough WH Branchek TA Zgombick JM Filla SA 《Bioorganic & medicinal chemistry letters》2004,14(1):167-170
Synthesis and evaluation of a series of 2,3,5- and 3,5-substituted furo[3,2-b]pyridines were undertaken in order to investigate their utility as bioisosteres of 5-HT(1F) receptor agonist indole analogues, 1-3. The replacement proved to be effective, providing compounds with similar 5-HT(1F) receptor affinity and improved selectivity when compared with the indole analogues. Through these studies we identified 4-fluoro-N-[3-(1-methyl-piperidin-4-yl)-furo[3,2-b]pyridin-5-yl]-benzamide (5), a potent and selective 5-HT(1F) receptor agonist with the potential to treat acute migraine. 相似文献
15.
Ronald C. Bernotas Steven Lenicek Schuyler Antane Derek C. Cole Boyd L. Harrison Albert J. Robichaud Guo Ming Zhang Deborah Smith Brian Platt Qian Lin Ping Li Joseph Coupet Sharon Rosenzweig-Lipson Chad E. Beyer Lee E. Schechter 《Bioorganic & medicinal chemistry》2009,17(14):5153-5163
A series of 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines 10a–z was prepared as novel 5-HT6 ligands. The best compounds were high affinity, full agonists at 5-HT6 receptors. Several agonists demonstrated good selectivity over other serotonergic and dopaminergic receptors. Acute administration of selective agonist 10e significantly increased extracellular GABA concentrations in rat frontal cortex. This compound also reduced adjunctive drinking behavior in the rat schedule-induced polydipsia assay, possibly predictive of efficacy in obsessive compulsive disorder and other anxiety related disorders. 相似文献
16.
Xiao Ding Luigi Piero Stasi Ming-Hsun Ho Baowei Zhao Hailong Wang Kai Long Qiongfeng Xu Yingxia Sang Changhui Sun Huan Hu Haihua Yu Zehong Wan Lizhen Wang Colin Edge Qian Liu Yi Li Kelly Dong Xiaoming Guan Feng Ren 《Bioorganic & medicinal chemistry letters》2018,28(9):1615-1620
Inhibition of LRRK2 kinase activity with small molecules has emerged as a potential novel therapeutic treatment for Parkinson’s disease. Herein we disclose the discovery of a 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amine series as potent LRRK2 inhibitors identified through a kinase-focused set screening. Optimization of the physicochemical properties and kinase selectivity led to the discovery of compound 7, which exhibited potent in vitro inhibition of LRRK2 kinase activity, good physicochemical properties and kinase selectivity across the kinome. Moreover, compound 7 was able to penetrate into the CNS, and in vivo pharmacology studies revealed significant inhibition of Ser935 phosphorylation in the brain of both rats (30 and 100?mg/kg) and mice (45?mg/kg) following oral administration. 相似文献
17.
Wyman PA Marshall HR Flynn ST King RJ Thompson M Smith PW Hadley MS Price GW Scott CM Dawson LA 《Bioorganic & medicinal chemistry letters》2005,15(21):4708-4712
An SAR study around the mixed 5-HT1ABD receptor antagonist SB-272183 found that introduction of cis-2,6-dimethyl substitution onto the piperazine ring was a key structural change, which imparted a combination of both excellent selectivity over the 5-HT1A and 5-HT1D receptors and low intrinsic activity. This led to the identification of the selective 5-HT1B receptor antagonist SB-616234. 相似文献
18.
The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine 总被引:2,自引:0,他引:2
Lin P Chang L Devita RJ Young JR Eid R Tong X Zheng S Ball RG Tsou NN Chicchi GG Kurtz MM Tsao KL Wheeldon A Carlson EJ Eng W Burns HD Hargreaves RJ Mills SG 《Bioorganic & medicinal chemistry letters》2007,17(18):5191-5198
SAR studies on amides, ureas, and vinylogous amides derived from pyrrolidine led to the discovery of several potent hNK(1) antagonists. One particular vinylogous amide (45b) had excellent potency, selectivity, pharmacokinetic profile, and functional activity in vivo. An in vivo rhesus macaque brain receptor occupancy PET study for compound 45b revealed an estimated Occ(90) approximately 300 ng/ml. 相似文献
19.
Earl Clarke Christopher I. Jarvis Maria B. Goncalves S. Barret Kalindjian David R. Adams Jane T. Brown Jason J. Shiers David M.A. Taddei Elodie Ravier Stephanie Barlow Iain Miller Vanessa Smith Alan D. Borthwick Jonathan P.T. Corcoran 《Bioorganic & medicinal chemistry》2018,26(4):798-814
A ligand-based virtual screening exercise examining likely bioactive conformations of AM 580 (2) and AGN 193836 (3) was used to identify the novel, less lipophilic RARα agonist 4-(3,5-dichloro-4-ethoxybenzamido)benzoic acid 5, which has good selectivity over the RARβ, and RARγ receptors. Analysis of the medicinal chemistry parameters of the 3,5-substituents of derivatives of template 5 enabled us to design a class of drug-like molecules with lower intrinsic clearance and higher oral bioavailability which led to the novel RARα agonist 4-(3-chloro-4-ethoxy-5-isopropoxybenzamido)-2-methylbenzoic acid 56 that has high RARα potency and excellent selectivity versus RARβ (2 orders of magnitude) and RARγ (4 orders of magnitude) at both the human and mouse RAR receptors with improved drug-like properties. This RARα specific agonist 56 has high oral bioavailability (>80%) in both mice and dogs with a good PK profile and was shown to be inactive in cytotoxicity and genotoxicity screens. 相似文献
20.
Tammy Ladduwahetty Myra Gilligan Alexander Humphries Kevin J. Merchant Rebecca Fish George McAlister Magnus Ivarsson Maria Dominguez Desmond O’Connor Angus M. MacLeod 《Bioorganic & medicinal chemistry letters》2010,20(12):3708-3712
Scaffold hopping from a non-basic series of 5-HT2A receptor antagonists developed in-house that possessed reduced activity in vivo enabled the discovery of a novel series of diaryl sulfones that gave excellent occupancy on oral dosing. Not only does this work further demonstrate that oral bioavailability of a given series can be enhanced by improving physicochemical parameters such as log P, but it corroborates the growing evidence that a protonated amine is not essential for affinity at aminergic GPCRs. 相似文献